CG Oncology (NASDAQ:CGON - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at Truist Financial in a report released on Tuesday, Benzinga reports. They currently have a $100.00 price target on the stock, up from their prior price target of $85.00. Truist Financial's target price suggests a potential upside of 24.38% from the company's previous close.
A number of other equities analysts have also recently issued reports on CGON. Guggenheim decreased their price objective on shares of CG Oncology from $90.00 to $89.00 and set a "buy" rating on the stock in a research report on Monday, November 9th. Weiss Ratings reiterated a "sell (d-)" rating on shares of CG Oncology in a report on Thursday, October 15th. Piper Sandler raised their target price on CG Oncology from $82.00 to $85.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. Wall Street Zen upgraded CG Oncology from a "strong sell" rating to a "sell" rating in a report on Saturday, November 7th. Finally, HC Wainwright upped their price target on CG Oncology from $100.00 to $115.00 and gave the company a "buy" rating in a research report on Tuesday. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, CG Oncology presently has a consensus rating of "Moderate Buy" and a consensus target price of $94.22.
Get Our Latest Stock Analysis on CG Oncology
CG Oncology Stock Performance
Shares of CG Oncology stock opened at $80.40 on Tuesday. CG Oncology has a 52-week low of $37.01 and a 52-week high of $93.95. The stock has a market capitalization of $7.18 billion, a price-to-earnings ratio of -29.55 and a beta of 0.35. The company has a fifty day moving average of $68.24 and a 200-day moving average of $66.70.
CG Oncology (NASDAQ:CGON - Get Free Report) last announced its quarterly earnings data on Friday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.19. The firm had revenue of $1.60 million for the quarter, compared to analysts' expectations of $0.55 million. CG Oncology had a negative return on equity of 24.58% and a negative net margin of 3,851.09%. On average, equities research analysts forecast that CG Oncology will post -3.00 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, Director Leonard E. Post sold 1,000 shares of the firm's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $62.06, for a total value of $62,060.00. Following the completion of the sale, the director directly owned 1,000 shares of the company's stock, valued at approximately $62,060. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 4.80% of the company's stock.
Hedge Funds Weigh In On CG Oncology
Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new position in shares of CG Oncology during the second quarter valued at $444,509,000. Bank of America Corp DE purchased a new position in shares of CG Oncology in the 2nd quarter worth about $69,978,000. Jefferies Financial Group Inc. bought a new position in CG Oncology in the 2nd quarter worth about $54,705,000. Toronto Dominion Bank boosted its stake in CG Oncology by 177.7% in the 3rd quarter. Toronto Dominion Bank now owns 798,676 shares of the company's stock worth $56,618,000 after purchasing an additional 511,044 shares in the last quarter. Finally, Seven Fleet Capital Management LP grew its position in CG Oncology by 24.5% during the 2nd quarter. Seven Fleet Capital Management LP now owns 1,886,236 shares of the company's stock valued at $134,017,000 after purchasing an additional 371,085 shares during the last quarter. Hedge funds and other institutional investors own 26.56% of the company's stock.
Trending Headlines about CG Oncology
Here are a few of the latest headlines about CGON:
- Positive Sentiment: In the PIVOT-006 Phase 3 trial, cretostimogene cut the risk of bladder-cancer recurrence by 68% versus surveillance (hazard ratio 0.32; p<0.0001). The company reported no Grade 3 or higher treatment-related adverse events or treatment-related discontinuations. The results address an estimated 50,000-patient group with no FDA-approved adjuvant treatment option. PIVOT-006 trial results
- Positive Sentiment: CG Oncology plans to use the results to support a second Biologics License Application (BLA) for intermediate-risk and high-grade Ta disease in Q2 2027. Separately, following FDA feedback, it expects to broaden its initial BLA for BCG-unresponsive disease to include high-grade papillary-only patients, with filing completion anticipated by March 2027.
- Negative Sentiment: The results are topline and based on preliminary analysis. The FDA could interpret the data differently, request additional studies, delay review, or approve a narrower indication than the company anticipates; cretostimogene remains investigational and is not yet FDA-approved.
About CG Oncology
(
Get Free Report)
CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company's research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CG Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.
While CG Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.